요약정보
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
- Resource Type
- Academic Journal
- Authors
- Zatreanu D; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Robinson HMR; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Alkhatib O; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Boursier M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Finch H; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Geo L; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Grande D; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Grinkevich V; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Heald RA; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Langdon S; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Majithiya J; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; McWhirter C; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Martin NMB; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Moore S; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Neves J; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Rajendra E; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Ranzani M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Schaedler T; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Stockley M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Wiggins K; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; Brough R; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Sridhar S; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Gulati A; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Shao N; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Badder LM; The Breast Cancer Now Research Unit, King's College London, London, UK.; Novo D; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Knight EG; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Marlow R; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Research Unit, King's College London, London, UK.; Haider S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Callen E; Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.; Hewitt G; The Francis Crick Institute, London, UK.; Schimmel J; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.; Prevo R; Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK.; Alli C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Ferdinand A; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Bell C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Blencowe P; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Bot C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Calder M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Charles M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Curry J; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Ekwuru T; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Ewings K; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Krajewski W; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; MacDonald E; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; McCarron H; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Pang L; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Pedder C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Rigoreau L; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Swarbrick M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Wheatley E; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Willis S; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Wong AC; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.; Nussenzweig A; Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.; Tijsterman M; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.; Tutt A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Research Unit, King's College London, London, UK.; Boulton SJ; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; The Francis Crick Institute, London, UK.; Higgins GS; Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK.; Pettitt SJ; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK. Stephen.Pettitt@icr.ac.uk.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Stephen.Pettitt@icr.ac.uk.; Smith GCM; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK. Graeme.Smith@artiospharma.com.; Lord CJ; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK. Chris.Lord@icr.ac.uk.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Chris.Lord@icr.ac.uk.
- Source
- Publisher:
Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN:20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE - Subject
- Language
- English